Summary
Claims about FDA-approved indications and some factual descriptions are not aligned with the provided FDA label excerpts. The provided label excerpts do not support these claims, and several additional claims concern a patient savings program that is not present in the label excerpts.
Category Scores
Accurate Statements
Vascepa is a prescription medication used to treat high triglycerides.
Partially supported by labeling that VASCEPA is indicated as an adjunct to diet to reduce triglyceride (TG) levels in adult patients with severe hypertriglyceridemia (Section 1). The excerpt does not support broader “high triglycerides” without specifying severe hypertriglyceridemia or the cardiovascular risk populations.
Unsupported Statements
Vascepa is prescribed for people with familial hypercholesterolemia.
The provided FDA label excerpt (Section 1) does not include familial hypercholesterolemia as an indication.
Familial hypercholesterolemia is a genetic disorder that causes high levels of low-density lipoprotein (LDL) cholesterol.
The provided FDA label excerpt does not describe familial hypercholesterolemia or its genetic/LDL characteristics.
Vascepa is also used to treat mixed dyslipidemia.
The provided FDA label excerpt (Section 1) does not list mixed dyslipidemia as an indication.
Mixed dyslipidemia is characterized by high levels of triglycerides and LDL cholesterol.
The provided FDA label excerpt does not define mixed dyslipidemia.
The Vascepa Savings Program is a patient assistance program designed to help eligible patients afford their Vascepa medication.
No patient savings program information is included in the provided FDA label excerpts.
The Vascepa Savings Program is administered by the manufacturer, Amarin Corporation.
No patient savings program information is included in the provided FDA label excerpts.
The Vascepa Savings Program is available to patients who are uninsured, underinsured, or have limited financial resources.
No patient savings program information is included in the provided FDA label excerpts.
To be eligible for the Vascepa Savings Program, patients must have a valid prescription for Vascepa and be uninsured or underinsured.
No patient savings program information is included in the provided FDA label excerpts.
To be eligible for the Vascepa Savings Program, patients must have an annual household income of $100,000 or less for individuals or $200,000 or less for families.
No patient savings program information is included in the provided FDA label excerpts.
To be eligible for the Vascepa Savings Program, patients must not have other prescription insurance coverage that would cover the cost of Vascepa.
No patient savings program information is included in the provided FDA label excerpts.
The Vascepa Savings Program offers discounted copays for enrolled patients.
No patient savings program information is included in the provided FDA label excerpts.
The Vascepa Savings Program may offer free Vascepa medication to patients who are uninsured or have limited financial resources.
No patient savings program information is included in the provided FDA label excerpts.
Patients can enroll in the Vascepa Savings Program online by visiting the Amarin Corporation website and completing an enrollment form.
No patient savings program information is included in the provided FDA label excerpts.
Patients can enroll in the Vascepa Savings Program by calling the Amarin Corporation patient assistance program hotline at 1-855-272-7901.
No patient savings program information is included in the provided FDA label excerpts.
Patients must provide proof of income and insurance status to enroll in the Vascepa Savings Program.
No patient savings program information is included in the provided FDA label excerpts.
Patients can use the Vascepa Savings Program in combination with other patient assistance programs, but may need to provide proof of income and insurance status to each program.
No patient savings program information is included in the provided FDA label excerpts.
Patients can contact the Amarin Corporation patient assistance program hotline to determine eligibility for the Vascepa Savings Program.
No patient savings program information is included in the provided FDA label excerpts.
Contradictions
AI Statement
Vascepa is prescribed for people with familial hypercholesterolemia.
Label Reference
Section 1 INDICATIONS AND USAGE (provided excerpt). Familial hypercholesterolemia is not listed as an indication.
AI Statement
Vascepa is also used to treat mixed dyslipidemia.
Label Reference
Section 1 INDICATIONS AND USAGE (provided excerpt). Mixed dyslipidemia is not listed as an indication.
AI Statement
Mixed dyslipidemia is characterized by high levels of triglycerides and LDL cholesterol.
Label Reference
Section 1 INDICATIONS AND USAGE (provided excerpt). No definition of mixed dyslipidemia is provided; therefore the claim is not supported by the label excerpt and cannot be verified.
Important Omissions
For the triglyceride-related indication, the label excerpt specifies more precise populations/conditions: (1) adjunct to maximally tolerated statin therapy to reduce risk of MI, stroke, coronary revascularization, and unstable angina requiring hospitalization in adults with elevated TG (≥150 mg/dL) and established cardiovascular disease or diabetes with 2+ additional risk factors; and (2) adjunct to diet to reduce TG levels in adults with severe hypertriglyceridemia (≥500 mg/dL).
Importance:
Moderate
No dosing, administration, contraindications, major warnings/precautions, drug interaction monitoring, or adverse reaction information was provided in the AI claims set, despite those being major label sections for safe prescribing context.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
High
The response includes indication claims (familial hypercholesterolemia; mixed dyslipidemia) that are not supported by the provided FDA label excerpts, which could lead to misapplication of the product outside labeled indications. The savings-program details are also unsupported by the provided label excerpts.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
Yes |
| Hallucination Risk |
High |
Recommendation
Not Aligned
Primary Issue
Major indication inaccuracies (familial hypercholesterolemia; mixed dyslipidemia) not present in the provided FDA label excerpts; savings-program claims are unsupported by the provided label excerpts.
Suggested Improvement
Rephrase indications to match the provided Section 1 language (adjunct to statin therapy for elevated TG with specified cardiovascular risk, or adjunct to diet for severe hypertriglyceridemia with TG ≥500 mg/dL). Remove or separately source patient savings-program details since they are not included in the provided FDA label excerpts.